CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: The dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients were largely monoclonal (Fig. 5A), whereas the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients were either oligoclonal or polyclonal (Fig. 5B).